Releasing the syndrome from captivity: why renaming PCOS to PMOS widens reproductive care beyond the anovulatory frame

Polycystic ovary syndrome (PCOS) has long been focused on the ovary and infertility aspects, rooted in the early observations by Stein and Leventhal (1935). The aggregated data, however, show that the syndrome has a wide comorbidity risk beyond fertility aspects involving several endocrine and metabolic derangements, yet without a true risk of ovarian cysts, benign or pathological, as expected with the old name. Moreover, with modern fertility care, women with the condition can reach cumulative childbirth rates comparable to those of unaffected women. The women may have spontaneous ovulations and pregnancies across the reproductive life course and, having high ovarian reserve, enter the menopause later. The endometrium and pregnancy complications have, however, been the blind spots in fertility care. Taking all this into account, in May 2026, a multi-step global consensus process culminating in a Lancet statement renamed the condition polyendocrine metabolic ovarian syndrome (PMOS), with transitional adoption already underway in current international guidance and consolidation into the next major international evidence-based guideline update scheduled for 2028. This opinion argues that the rename is not a cosmetic relabelling but a clinical mandate to widen fertility and pregnancy care, address fragmented care across primary, fertility, obstetric, and endocrine services, and acknowledge the endocrine, metabolic, psychological, and oncological burden. For Human Reproduction’s readership, the 2028 guideline update is the concrete deadline around which language, registry coding, trial protocols, education, and clinical practice can align.